Research on Genetic Risk Score & Prostate Cancer Outcomes to be Highlighted in 2022 ASCO Genitourinary Cancers Symposium Press Program

For immediate release
February 3, 2022


Rachel Cagan Facci

ALEXANDRIA, Va. – Findings on a scoring algorithm for predicting the risk of developing metastatic or fatal prostate cancer will be highlighted in the 2022 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium’s official Press Program. Studies featured in the Press Program are among the nearly 600 abstracts that will be presented at the Symposium. 

The 2022 ASCO Genitourinary Cancers Symposium, taking place February 17-19 in San Francisco, CA, and online, will bring together oncology professionals from around the globe for presentations and discussions surrounding new, innovative findings in genitourinary cancer treatment, research, and care.

Abstracts will be publicly released on on Monday, February 14, at 5:00 p.m. ET and the embargo will lift at that time. The following abstract will be highlighted in a press release as a part of the Press Program: 

  • Evaluating a polygenic hazard score to predict risk of developing metastatic or fatal prostate cancer in the multi-ancestry Million Veteran Program cohort. (Abstract 155) 


Apply for/renew ASCO media credentials: Reporters with valid ASCO media credentials will be able to access embargoed press materials and view online presentations from the 2022 ASCO Genitourinary Cancers Symposium. Please visit ASCO’s Media Headquarters at to request credentials or to ensure your credentials are up to date.  

Attend the Symposium in person: Credentialed media who would like to attend the meeting in-person can contact Rachel Cagan at to register. All in-person attendees must be fully vaccinated (including required booster) against COVID-19. Visit our Health and Safety page for more details. 

About ASCO: 

Founded in 1964, the American Society of Clinical Oncology, Inc. (ASCO®) is committed to the principle that knowledge conquers cancer. Together with the Association for Clinical Oncology, ASCO represents nearly 45,000 oncology professionals who care for people living with cancer. Through research, education, and promotion of high quality, equitable patient care, ASCO works to conquer cancer and create a world where cancer is prevented or cured, and every survivor is healthy. Conquer Cancer, the ASCO Foundation, supports ASCO by funding groundbreaking research and education across cancer’s full continuum. Learn more at, explore patient education resources at www.Cancer.Net, and follow us on Facebook, Twitter, LinkedIn, and YouTube.